First Drug Slows ALS Progression in Early Trial
The drug riluzole shows potential to delay crippling symptoms and death in a French trial of 155 patients, with survival reportedly nearly doubled in some cases. Skeptics caution results may reflect a statistical fluke and stress the need for Rothstein's larger study involving about 959 patients to confirm efficacy.
MENTIONED IN THIS ARTICLE
Ing
Eythe
Lou Gehrig
Jeffrey Rothstein
Johns Hopkins University
Jacob Javits
David Niven
Dennis Day
United States
Rhone-Poulenc _ Rover
Gilbert Bensimon
Hopital de la Pitie-Salpetriere
Paris
Rothstein
France
Belgium
Lewis Rowland
Columbia-Presbyterian Medical Center
New York
Study links city traffic to lower cardiac arrest survival
A Chicago and New York study shows only 1.4 percent of out of hospital cardiac arrest patients survive in New York and 1.3 percent in Chicago, with urban areas faring better or worse by density. Researchers urge more training for police, firefighters, and bystanders in CPR and defibrillation to improve chain of survival.
MENTIONED IN THIS ARTICLE
Chicago
U.S
Gary Lombardi
New York City
Lombardi
Journal of
American Medical Association
American Heart Association
New York
Lance Becker
University of Chicago
Also Mentioned on This Page
Lou Gehrig’s
The
Associated Press
Ila Ie
Seo DO
Phoenix E. Baseline
E. Ray Rd
E. Roosevelt St
N. 32Nd St
Phoenix
W. Greenway Rd
W. Indian School
W. Northern Ave
Apache Junction
Chandler
Mesa
W. Broadway
Tempe
Bank of America
Investment Services
BA Investment Services
New York Stock Exchange
Wall Street
Blane
BA Investment Services, Inc
BankAmerica Company
U.S. Treasury
Federal Deposit Insurance Corporation
BAIS
NYSE
SIPC